You are viewing a javascript disabled version of the site. Please enable Javascript for this site to function properly.
Go to headerGo to navigationGo to searchGo to contentsGo to footer
In content section. Select this link to jump to navigation

Of patents and patent disputes: The TNFα patent files. Part 1: Humira

Article type: Research Article

Authors: Storz, Ulrich

Affiliations: Michalski ⋅ Hüttermann Patent Attorneys, Düsseldorf, Germany. E-mail: [email protected]

Abstract: This article discusses the patent strategy underlying the world's best selling drug, AbbVie's Humira®. Despite a non-optimal starting position, AbbVie has established an extensive portfolio to fend off biosimilar competition. This article is the first part of a trilogy that discusses IP issues related to anti-Tumor Necrosis factor α (TNFα) biologics.

Keywords: Adalimumab, patent, Humira, biosimilars, dosage, formulation

DOI: 10.3233/HAB-160300

Journal: Human Antibodies, vol. 25, no. 1-2, pp. 1-16, 2017

Published: 20 February 2017
Price: EUR 27.50
Show more